Pemvidutide

Synonimy: LY3305677, OXM-3 analog, Glucagon/GLP-1 receptor dual agonist

In the race to develop next-generation therapies for obesity and metabolic dysfunction, pemvidutide has emerged as a promising contender. As a dual agonist targeting both the glucagon and GLP-1 receptors, it is being evaluated for its potential to deliver meaningful weight loss alongside improvements in lipid profiles and liver health. The compound has drawn particular interest from researchers exploring treatments for metabolic dysfunction-associated steatohepatitis (MASH) and related conditions, where its balanced receptor activity may offer advantages over single-target approaches.

Pemvidutide is a synthetic peptide analog of oxyntomodulin, a naturally occurring hormone that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual mechanism is designed to harness the appetite-suppressing and insulinotropic effects of GLP-1 while leveraging glucagon’s ability to increase energy expenditure and promote lipolysis. The peptide backbone incorporates specific modifications to extend its half-life and improve stability, making it suitable for once-weekly subcutaneous administration in clinical settings.

Manufactured under stringent conditions, pemvidutide is available as a high-purity lyophilized powder, typically ≥98% as determined by HPLC. It is supplied for research and development purposes, including preclinical studies, formulation development, and clinical trial material sourcing. Its well-characterized profile and consistent batch-to-batch quality make it a reliable choice for organizations investigating dual receptor agonists for metabolic diseases.

Product Overview & Composition

Pemvidutide is a 39-amino acid peptide engineered to mimic the activity of oxyntomodulin, a gut hormone that regulates appetite and energy balance. The sequence incorporates non-natural amino acids and a fatty acid side chain to enhance plasma stability and prolong its duration of action. This design allows for less frequent dosing compared to native oxyntomodulin, which has a very short half-life.

The peptide is produced via solid-phase peptide synthesis, followed by purification using preparative HPLC. Each batch is rigorously tested for identity, purity, and biological activity to ensure it meets the demands of advanced research. The lyophilized powder is highly soluble in aqueous solutions, facilitating formulation into injectable dosage forms.

Key Applications

• Obesity research: Investigated for its potential to induce weight loss through combined GLP-1 and glucagon receptor activation.
• Metabolic dysfunction-associated steatohepatitis (MASH): Studied for its effects on liver fat reduction and inflammation.
• Type 2 diabetes: Explored for glycemic control and improvement of lipid parameters.
• Preclinical pharmacology: Used in animal models to elucidate dual receptor signaling pathways.
• Formulation development: Employed in the design of long-acting injectable depots or sustained-release systems.

Quality & Standards

Packaging & Supply

• Opakowanie: Supplied in amber glass vials with rubber stoppers and aluminum crimp seals, under inert gas.
• MOQ: 1 mg (research quantities); bulk orders negotiable.
• Czas realizacji: 3–5 dni roboczych (towary dostępne w magazynie)
• Dokumentacja: COA, MSDS, and TDS provided with each shipment.

Zapytanie ofertowe

• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com